Cancer research
A recent study published in the Journal for ImmunoTherapy of Cancer has revealed that AstraZeneca's AZD5863, a bispecific T-cell engager (TCE), shows potent anti-tumor activity while inducing limited levels of cytokines. This breakthrough in cancer therapy has significant implications for the treatment of gastric, pancreatic, and esophageal adenocarcinomas.
Cancer research
A study published in Blood Advances has investigated the treatment patterns and clinical outcomes for patients with mantle cell lymphoma who experienced progression-of-disease (POD) following CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy. The research identified 135 patients (35% of 384 total patients) who experienced POD, with most patients (64%) having
Cancer
Researchers from Tianjin Medical University Cancer Institute and Hospital have developed a multifunctional nanoplatform, IN@OMV-PDL1nb, designed to simultaneously inhibit tumor-associated macrophages (TAMs) and the immune checkpoint molecule PD-L1 within the tumor microenvironment (TME). This innovative approach effectively alleviates immune suppression induced by TAMs and PD-L1, offering a promising strategy
Cancer
Researchers at the University of North Carolina Chapel Hill have made significant progress in the development of chimeric antigen receptor (CAR) T cells, which have shown promise in treating lymphoid malignancies. However, despite their potential benefits, CAR T cells have yet to demonstrate clinical benefits in solid tumors. As a
Cancer
Research conducted at the University of Groningen in Groningen, Netherlands, has shed light on a new approach to cancer treatment. The study, which was funded by the Dutch Cancer Society, Maurits en Anna de Kock Stichting, and De Cock-Hadders, has identified a novel fusion protein that efficiently redirects anti-cytomegalovirus (CMV)
Cancer
Researchers at the University of Sao Paulo have made significant strides in understanding the mechanism and signalling pathways of CAR-T cell therapy, a state-of-the-art approach in cell and immunotherapy. By employing global proteomics, the team identified proteins as molecular effectors of anti-CD19 CAR-T cell treatment during the early stages of
Cancer
A new mathematical model developed by a research team led by Paul Newton has the potential to revolutionize cancer treatment by applying principles of game theory to the complex interactions between cancer cells, healthy cells, and the immune system. The model predicts the outcome of these interactions, known as the
Cancer
Current cancer research has highlighted the limitations of immunotherapy in treating solid tumors, with a minority of patients benefiting from this treatment strategy. A recent study by researchers at the University of California Los Angeles (UCLA) has identified a critical limitation - T cell exhaustion - which prevents effective cancer
Cancer
Scientists at the University of California, Los Angeles (UCLA) have made a groundbreaking discovery in genetically engineered stem cell research, enabling patients to continuously produce cancer-fighting T cells. This novel therapeutic strategy, as published in Nature Communications, uses stem cells as an "internal factory" to generate tumor-targeting immune
Cancer
Researchers at the University of California, Los Angeles (UCLA), have made a significant discovery in the field of cancer treatment. A new study has demonstrated the effectiveness of tandem cell therapies involving autologous T cells and hematopoietic stem cells engineered to express the NY-ESO-1 TCR for the treatment of solid
Cancer
Researchers at King Abdulaziz University, led by Ahdab A. Alsaieedi and Kawther A. Zaher, have been instrumental in advancing the field of cancer immunotherapy, particularly in the realm of Chimeric Antigen Receptor (CAR)-T cell therapy. This innovative approach harnesses the adaptive immune system to selectively target and eradicate cancer
Cancer
Researchers from China have made a significant breakthrough in cancer immunotherapy by developing oxygen-driven Prussian blue nanomotors that disrupt the redox state to induce disulfide death in tumor cells. This innovative therapy has the potential to induce long-term protection against cancer by promoting antigen presentation and increasing cytotoxic T lymphocytes
